Steve Mao

Main text Over the past five years, Cancer Cell has undergone a transformative evolution, reflecting the increasing multidisciplinary and integrative nature of cancer research. As editor-in-chief, it has been both a privilege and a profound responsibility to guide this journal through a period of significant change and growth, ensuring that it remains at the forefront of cancer research while adapting to the evolving needs of the scientific community.

Therapeutic advances in immune checkpoint blockade (ICB) therapies have significantly improved cancer immunotherapy, particularly for solid tumors.

Author contributions Experiment design, F.B., N.Z., B.I., and X.X.; bioinformatic analysis, X.X.; data analysis assistance, J.B., J.Z., X.Z., F.L., W.W., and M.W.; sample and information collection, X.X., J.Z., Y.S., Y.M., H.D., Y.G., K.H., D.Z., Y.L., F.X., J.X., H.L., J.T., L.